CPC - Since several dates have passed, Trial Court can be requested to hear two applications before summons in suit and notice in applications are served on Respondent: HC (See 'Legal Desk') IBC - Application filed u/s 9 of IBC can be admitted as debt due remains unpaid despite demand made: NCLT (See 'Legal Desk') Govt lifts export ban on Bamboo Charcoal (See 'Corp Brief') Notices issued to Ola and Uber for unfair trade practices (See 'Corp Brief') Agri-tech Start-ups critical to India's future economy: Minister (See 'Corp Brief') FM participates in Annual Day commemoration of CCI (See 'Corp Brief') Copyright Act, 1957 - Offence u/s 63 of Copyright Act is a cognizable and non-bailable offence: SC (See 'Legal Desk') IBC - To regain control of Corporate Debtor (MSME) Management/Promoters/Erstwhile Directors are not required to compete with other Resolution Applicants: NCLAT (See 'Legal Desk') GeM, SEWA ink MoU to enable engagement of last-mile women-led enterprises (See 'Corp Brief') NCLT Rules, 2016 - Adjudicating Authority has power in terms of Rule 49(2) to recall any ex-parte order if sufficient cause is shown: NCLAT (See 'Legal Desk') IBC - Land owner intending to share profits emanating from agreed venture, by way of MoU, is a Financial Creditor as defined u/s 5: NCLAT (See 'Legal Desk') CCI approves merger by absorption of Covidshield Technologies into Biocon Biologics (See 'Corp Brief') CCI okays acquisition of majority stake in SMW Ispat by OFB Tech (See 'Corp Brief') CCI nod to Sanoti Properties' shareholding in Magma HDI General Insurance (See 'Corp Brief') Proceedings under SARFAESI evaporate once CIRP is initiated under IBC: SC (See 'Legal Desk') Department of Posts inks partnership with GeM and CSC (See 'Corp Brief') Karnataka launches own MyGov - 17th State in India (See 'Corp Brief') Pradhan reviews progress made under NETF and NDEAR (See 'Corp Brief') SEBI Act - Mere non-supply of documents cannot be treated as non-cooperation by appellants: SAT (See 'Legal Desk')

CCI okays internal acquisition by Glaxo Smith Kline

Published: Jan 24, 2022

By TIOLCorplaws News Service

NEW DELHI, JAN 24, 2022: THE Competition Commission of India (CCI) approves acquisition by GlaxoSmithKline Consumer Healthcare Overseas Limited and GlaxoSmithKline Consumer Healthcare UK Trading Limited (Acquirers) of shareholding in GlaxoSmithKline Asia Private Limited (Target) under Section 31(1) of the Competition Act, 2002.

The Proposed Combination involves collective acquisition of 100% shares of the Target by the Acquirers. Further, prior to the proposed combination, GSKAPL will acquire the trademarks pertaining to "Iodex" and "Ostocalcium" brands in India alongwith the legal, economic, commercial and marketing rights of such brands and other associated assets (GSK Consumer Brands) from GlaxoSmithKline Pharmaceuticals Limited.

GlaxoSmithKline Consumer Healthcare Overseas Limited is a wholly-owned subsidiary of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited ("GSK CH HoldCo"). It is a part of the overall GlaxoSmithkline (GSK) group and its principal activity is to act as an investment holding company for GSK CH HoldCo and its subsidiaries.

GlaxoSmithKline Consumer Healthcare UK Trading Limited is a part of the overall GSK group and is a wholly-owned subsidiary of GSK CH HoldCo. It is engaged in the distribution and sale of consumer healthcare products, manufacturing, marketing, providing management services to the consumer healthcare group and providing research and development services to other consumer healthcare companies within the GSK group.

GSKAPL is a consumer healthcare company that is engaged in the marketing and distribution of oral healthcare products under various brand names such as Sensodyne, Parodontax, Polident and over-the-counter medicines products under the brand names such as Crocin, ENO.